{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:30:14Z","timestamp":1794562214142,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012729","name":"Case Western Reserve University Clinical and Translational Science Collaborative","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008136","name":"Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajo.2026.05.046","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:18:16Z","timestamp":1780327096000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immune Checkpoint Inhibitor\u2013Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes"],"prefix":"10.1016","volume":"289","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-5845","authenticated-orcid":false,"given":"Victor","family":"Bellanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Schulgit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-5051","authenticated-orcid":false,"given":"Khaled A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy B.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-1097","authenticated-orcid":false,"given":"Gabriel Castilho S.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-9504","authenticated-orcid":false,"given":"Nitesh","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-9515","authenticated-orcid":false,"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-0717","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2026.05.046_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.046_bib0002","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ijc.33266","article-title":"Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018","volume":"148","author":"Board","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajo.2026.05.046_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102254","article-title":"Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: a retrospective study from the United States database","volume":"81","author":"Adhikari","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.046_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a surveillance, epidemiology, and end results database-based Study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ajo.2026.05.046_bib0005","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.046_bib0006","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.046_bib0007","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.046_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ajo.2026.05.046_bib0009","article-title":"Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database","volume":"14","author":"Kuo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajo.2026.05.046_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.046_bib0011","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.ajo.2026.05.046_bib0012","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jamaoncol.2025.0985","article-title":"Harm-benefit balance of immune checkpoint inhibitors in non-small cell lung cancer","volume":"11","author":"Heyward","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ajo.2026.05.046_bib0013","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1148\/rg.2017170085","article-title":"Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings","volume":"37","author":"Wang","year":"2017","journal-title":"Radiographics"},{"issue":"10","key":"10.1016\/j.ajo.2026.05.046_bib0014","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ajo.2026.05.046_bib0015","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","volume":"28","author":"Atkins","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.046_bib0016","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ajo.2026.05.046_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/605478","article-title":"Clinical development of immune checkpoint inhibitors","volume":"2015","author":"Ito","year":"2015","journal-title":"Biomed Res Int"},{"issue":"10304","key":"10.1016\/j.ajo.2026.05.046_bib0018","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.046_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.ajo.2026.05.046_bib0020","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00103-020-03221-9","article-title":"[Checkpoint inhibitors for cancer therapy]","volume":"63","author":"Zander","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.046_bib0021","doi-asserted-by":"crossref","first-page":"980","DOI":"10.21873\/invivo.14254","article-title":"Onset and outcomes of immune-related adverse events in genitourinary cancer treated with immune checkpoint inhibitors","volume":"40","author":"Kato","year":"2026","journal-title":"In Vivo"},{"key":"10.1016\/j.ajo.2026.05.046_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.046_bib0023","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.046_bib0024","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.21873\/anticanres.17595","article-title":"Immune checkpoint inhibitor-induced uveitis: disproportionality and timing analyses of the Japanese pharmacovigilance database","volume":"45","author":"Ide","year":"2025","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.046_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.oret.2025.11.001","article-title":"Immune checkpoint inhibitor-associated uveitis: predictors and survival impact","volume":"10","author":"Chew","year":"2026","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.046_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.04-0961","article-title":"Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens","volume":"46","author":"van Dinten","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.046_bib0027","first-page":"81","article-title":"Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma","volume":"10","author":"Carrel","year":"1990","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.046_bib0028","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1076\/ceyr.16.5.487.7047","article-title":"Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived)","volume":"16","author":"Diebold","year":"1997","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.046_bib0029","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.05-1547","article-title":"Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens","volume":"47","author":"Sugita","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.05.046_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.05.046_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-016-0412-4","article-title":"Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes","volume":"11","author":"Lavezzo","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ajo.2026.05.046_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102454","article-title":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database","volume":"111","author":"Anquetil","year":"2020","journal-title":"J Autoimmun"},{"issue":"22","key":"10.1016\/j.ajo.2026.05.046_bib0033","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ajo.2026.05.046_bib0034","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2026.05.046_bib0035","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:17:23Z","timestamp":1794561443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0002939426002989"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.046","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}